NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 74 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,276 | -56.7% | 1,193,971 | +4.8% | 0.01% | -58.3% |
| Q2 2023 | $2,948 | -22.9% | 1,138,843 | +21.4% | 0.01% | -29.4% |
| Q1 2023 | $3,824 | +31.2% | 938,434 | +61.5% | 0.02% | +21.4% |
| Q4 2022 | $2,914 | -98.6% | 581,223 | +3377.0% | 0.01% | +1300.0% |
| Q2 2022 | $214,000 | -7.0% | 16,716 | +10.3% | 0.00% | 0.0% |
| Q1 2022 | $230,000 | +666.7% | 15,153 | +770.9% | 0.00% | – |
| Q4 2021 | $30,000 | -64.7% | 1,740 | -59.6% | 0.00% | – |
| Q2 2021 | $85,000 | -54.3% | 4,305 | -54.5% | 0.00% | -100.0% |
| Q2 2020 | $186,000 | +181.8% | 9,452 | +76.9% | 0.00% | – |
| Q1 2020 | $66,000 | – | 5,343 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |